What Novo is targeting next
Novo Nordisk is weighing a move into treatments for hair loss while building out its direct-to-consumer business. The company grouped hair loss with addiction and menopause as potential areas that fit its scientific capabilities and growing skill in selling prescription medicines straight to patients. Chief Scientific Officer Martin Lange pointed to endocrinology's role in some of today's hair-loss research and said, "We could leverage our scientific knowledge potentially moving into that space." He added, "It's not necessarily what we'll pursue first, but that would be a clear possibility."
Why the strategy is shifting
Novo ceded the obesity lead to Eli Lilly and is working to broaden the impact of its GLP-1 drugs while branching into new growth areas as its blockbusters face US and European patent cliffs as the 2030s approach. The company also plans to push faster on its internal pipeline and evaluate bolt-on deals. It is scouting new options in heart disease, liver disorders and blood disorders, with Lange noting that cardiology programs would likely take longer to develop. US rival Lilly is likewise exploring adjacent fields that dovetail with obesity, including women's health.
Timelines, trials and potential deals
Lange said some consumer-focused programs could have shorter paths to market and may arrive around the turn of the decade. He also left the door open to in-licensing or partnerships for candidates that are already closer to approval. Notably, hair loss is not among the eight conditions he expects to advance into mid-stage studies before this year ends or in the early part of next year.
New opportunities in health remind investors to keep protecting and growing their savings. Join Briefs Finance CEO Jaspreet Singh on September 29th for a FREE live investor workshop, How to Profit From A Dollar That's Losing its Value, where he shows how we're spotting investment opportunities as the dollar falls. Save your spot.
Market reaction and the stakes for your wallet
Investors wanted more specifics in Novo's turnaround presentation, and the stock took a hit. Shares fell as much as 1.8% Tuesday in Copenhagen, then steadied around midday. "Confidence is gone, as shown yesterday by the reaction, and it takes time and hard work to build that back," Chief Executive Officer Mike Doustdar said. He added that Novo will pursue spots where its direct-to-consumer know-how gives it a chance "to win," and, "We need to start somewhere and then we need to search everywhere." The potential prize is large: VeraDermics pegs the U.S. population with pattern hair loss at about 80 million, split between roughly 50 million men and about 30 million women, and says there are currently no approved oral therapies for them. If Novo turns its DTC muscle and hormone expertise toward that gap, it could reshape a mass-market category that everyday consumers already care about.
Staying focused on long term goals helps you weather change and build wealth. Our CEO Jaspreet Singh is hosting a FREE live investor workshop, How to Profit From A Dollar That's Losing its Value, on September 29th. Sign up free to join him live.
